Equity and efficiency in HIV‐treatment in South Africa: the contribution of mathematical programming to priority setting
- 1 September 2009
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 19 (10) , 1166-1180
Abstract
The HIV‐epidemic is one of the greatest public health crises to face South Africa. A health care response to the treatment needs of HIV‐positive people is a prime example of the desirability of an economic, rational approach to resource allocation in the face of scarcity. Despite this, almost no input based on economic analysis is currently used in national strategic planning.While cost‐utility analysis is theoretically able to establish technical efficiency, in practice this is accomplished by comparing an intervention's ICER to a threshold level representing society's maximum willingness to pay to avoid death and improve health‐related quality of life. Such an approach has been criticised for a number of reasons, including that it is inconsistent with a fixed budget for health care and that equity is not taken into account. It is also impractical if no national policy on the threshold exists. As an alternative, this paper proposes a mathematical programming approach that is capable of highlighting technical efficiency, equity, the equity/efficiency trade‐off and the affordability of alternative HIV‐treatment interventions. Government could use this information to plan an HIV‐treatment strategy that best meets equity and efficiency objectives within budget constraints. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- THE BURDEN OF HIV/AIDS IN THE PUBLIC HEALTHCARE SYSTEMSouth African Journal of Economics, 2008
- Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d’Ivoire: a trial-based analysisAIDS, 2005
- An investigation into the health-related quality of life of individuals living with HIV who are receiving HAARTAIDS Care, 2005
- Estimating resource needs for HIV/AIDS health care services in low-income and middle-income countriesHealth Policy, 2004
- Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?The Lancet, 2004
- Initiating highly active antiretroviral therapy in sub-Saharan AfricaAIDS, 2004
- CD4 and total lymphocyte counts as predictors of HIV disease progressionQJM: An International Journal of Medicine, 1996
- Cost effectiveness/utility analysesJournal of Health Economics, 1992
- Applications of cost-benefit analysis to health careJournal of Health Economics, 1987
- Modeling Resource Allocation for Child SurvivalPopulation and Development Review, 1984